Patients with PAL usually have a poor prognosis.[1,2,9] Recently, studies have suggested that BCL-2 and MYC co-expression predict poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL), but there are few reports on BCL-2 and MYC co-expression in patients with PAL.[10–12]. Here, MYC is linked to diffuse large B-cell lymphoma.